FDA rejects new obesity drug Qnexa

Oct 30, 2010

The US Food and Drug Administration has rejected a marketing request by Vivus for its new obesity treatment called Qnexa, because it considers it a health risk, the California-based biotech firm said in a statement.

The FDA issued a letter "to communicate its decision that the NDA (New Drug Application for Qnexa) cannot be approved in its present form," the company said.

In its decision, the FDA followed the July recommendations of its expert panel on endocrinological and metabolic drugs, who found by six votes to one abstention that Qnexa could cause potential heart problems.

Qnexa was the first obesity drug submitted to the FDA in a decade.

It combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

The FDA on October 8 requested US pharmaceutical company Abbott Laboratories to pull its obesity drug Meridia from the US market after European tests found the key ingredient increased the risk of serious heart problems.

And last week, the US health panel rejected a marketing request for 2011 for weight-loss drug Lorcaserin, made by also California-based Arena Pharmaceuticals, after tests determined it caused tumors in laboratory rats.

While a high percentage of Americans are overweight or obese, there are few medical treatments, and those on the market can have side effects including increased and intestinal gas.

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Vivus weight loss drug faces FDA panel this week

Jul 13, 2010

(AP) -- Vivus Inc.'s experimental drug Qnexa was effective in cutting weight, the Food and Drug Administration said Tuesday, while acknowledging lingering concerns over the drug's nervous system and psychiatric side effects.

FDA rejects highly-anticipated diet drug Qnexa

Oct 29, 2010

(AP) -- Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.

FDA panel rejects experimental weight loss pill

Jul 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

Diet drugs face tough test before FDA

Sep 17, 2010

There has never been a magic prescription to help millions of obese Americans lose weight. Whether one is any closer to reality is now under scrutiny.

FDA to review first of 3 new weight loss drugs

Jul 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

TheAlzheimersDoc
5 / 5 (2) Oct 31, 2010
The FDA rightfully has declined the request of Vivus to market Qnexa.
We don't need another weight loss drug that has phentermine as a major component. The risk for coronary complications are just too great.
It is a risk that few physicians are willing to take anymore with their patients.
Bob_B
1 / 5 (2) Oct 31, 2010
People are proving they are pigs at the gut level. I agree some people are overweight due to medical reasons, but most just...pig-like, and they like it. Survival of the fittest should eliminate those genetic failures and make room for others, in my hopeful opinion.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.